 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper128th MAINE LEGISLATURE
FIRST REGULAR SESSION-2017
Legislative Document No. 1407
S.P. 485 In Senate, April 11, 2017
An Act  Regarding Prescription  Drug Step Therapy
Reference to the Committee on Insurance  and Financial Services suggested and  ordered 
printed.
HEATHER  J.R. PRIEST
Secretary of the Senate
Presented by Senator ROSEN of Hancock.
Cosponsored by Representative PIERCE  of Dresden  and
Senators: CARSON of Cumberland, DOW  of Lincoln, GRATWICK of Penobscot,  
Representatives: HARLOW of Portland, MALABY of Hancock,  POULIOT of Augusta, 
SANBORN of Portland,  VACHON of Scarborough.

 
 Page 1 - 128LR1195(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  24-A MRSA ยง4320 -K is enacted to read:  2 
ยง4320 -K.  Step therapy  3 
1.  Definitions.  As used in this section, unless the context otherwise indicates, the 4 
following terms have the following me anings.  5 
A.  "Clinical practice guidelines" means a systematically developed statement to 6 
assist prescriber and patient decisions about appropriate health care for specific 7 
clinical circumstances and conditions.  8 
B.  "Clinical review criteria" means the writ ten screening procedures, decision 9 
abstracts, clinical protocols and practice guidelines used by an insurer, health plan or 10 
utilization review organization to determine the medical necessity and 11 
appropriateness of health care services.  12 
C.  "Medically neces sary" means health services and supplies that, under the 13 
applicable standard of care, are appropriate to improve or preserve health, life or 14 
function; to slow the deterioration of health, life or function; or for the early 15 
screening, prevention, evaluation , diagnosis or treatment of a disease, condition, 16 
illness or injury.  17 
D.  "Step therapy override exception determination" means a determination based on 18 
a review of a patient's or prescriber's request for an override, along with supporting 19 
rationale and doc umentation, that the step therapy protocol should be overridden in 20 
favor of immediate coverage of the health care provider's selected prescription drug.  21 
E.  "Step therapy protocol" means a protocol that establishes a specific sequence in 22 
which prescription  drugs for a specified medical condition are medically necessary 23 
for a particular patient and are covered under a pharmacy or medical benefit by an 24 
insurer or health plan, including self -administered and physician -administered drugs.  25 
F.  "Utilization revie w organization" means an entity that conducts a utilization 26 
review, other than an insurer or health plan performing a utilization review for its 27 
own health benefit plans.  28 
2.  Clinical review criteria.  Clinical review criteria used to establish a step ther apy 29 
protocol must be based on clinical practice guidelines that:  30 
A.  Recommend that the prescription drugs be taken in the specific sequence required 31 
by the step therapy protocol;  32 
B.  Are developed and endorsed by a multidisciplinary panel of experts that manages 33 
conflicts of interest among the members of the writing and review groups by:  34 
(1)  Requiring members to disclose any potential conflicts of interest with 35 
entities, including insurers, health plans and pharmaceutical manufacturers, and 36 
recuse themsel ves from voting if they have a conflict of interest;  37 
 
 Page 2 - 128LR1195(01) -1 
 (2)  Using a methodologist to work with writing groups to provide objectivity in 1 
data analysis and ranking of evidence through the preparation of evidence tables 2 
and facilitating consensus; and  3 
(3)  Offe ring opportunities for public review and comments;  4 
C.  Are based on high -quality studies, research and medical practice;  5 
D.  Are created by an explicit and transparent process that:  6 
(1)  Minimizes biases and conflicts of interest;  7 
(2)  Explains the relatio nship between treatment options and outcomes;  8 
(3)  Rates the quality of the evidence supporting recommendations; and  9 
(4)  Considers relevant patient subgroups and preferences; and  10 
E.  Are continually updated through a review of new evidence, research and n ewly 11 
developed treatments.  12 
3.  Absence of clinical practice guidelines.  In the absence of clinical practice 13 
guidelines that meet the requirements in subsection 2, peer -reviewed publications may be 14 
substituted.  15 
4.  Consideration of atypical populations and  diagnoses.  When establishing a step 16 
therapy protocol, a utilization review organization shall also take into account the needs 17 
of atypical patient populations and diagnoses when establishing clinical review criteria.  18 
5.  Construction.  This section may n ot be construed to require insurers, health plans 19 
or the State to set up a new entity to develop clinical review criteria used for step therapy 20 
protocols.  21 
6.  Exceptions process.  When coverage of a prescription drug for the treatment of 22 
any medical condit ion is restricted for use by an insurer, health plan or utilization review 23 
organization through the use of a step therapy protocol, the patient and prescriber must 24 
have access to a clear, readily accessible and convenient process to request a step therapy 25 
override exception determination from that insurer, health plan or utilization review 26 
organization.  27 
A.  An insurer, health plan or utilization review organization may use its existing 28 
medical exceptions process to provide step therapy override exception 29 
determinations, and the process established must be easily accessible on the insurer's, 30 
health plan's or utilization review organization's website.  31 
B.  An insurer, health plan or utilization review organization shall expeditiously grant 32 
a step therapy overri de exception determination if:  33 
(1)  The required prescription drug is contraindicated or will likely cause an 34 
adverse reaction in or physical or mental harm to the patient;  35 
(2)  The required prescription drug is expected to be ineffective based on the 36 
know n clinical characteristics of the patient and the known characteristics of the 37 
prescription drug regimen;  38 
 
 Page 3 - 128LR1195(01) -1 
 (3)  The patient has tried the required prescription drug while under the patient's 1 
current or previous health insurance or health benefit plan, or an other prescription 2 
drug in the same pharmacologic class or with the same mechanism of action, and 3 
the prescription drug was discontinued due to lack of efficacy or effectiveness, 4 
diminished effect or an adverse event;  5 
(4)  The required prescription drug is  not in the best interest of the patient, based 6 
on medical necessity; or  7 
(5)  The patient is stable on a prescription drug selected by the patient's health 8 
care provider for the medical condition under consideration while on a current or 9 
previous health in surance or health benefit plan.  10 
C.  Upon the granting of a step therapy override exception determination, the insurer, 11 
health plan or utilization review organization shall authorize coverage for the 12 
prescription drug prescribed by the prescriber.  13 
D.  An in surer, health plan or utilization review organization shall respond to a 14 
request for a step therapy override exception determination or an appeal of a 15 
determination within 72 hours of receipt of the request.  In cases when exigent 16 
circumstances exist, an i nsurer, health plan or utilization review organization shall 17 
respond within 24 hours of receipt of the request.  If a response by an insurer, health 18 
plan or utilization review organization is not received within the time required under 19 
this paragraph, the exception or appeal is granted.  20 
E.  An insured may appeal a step therapy override exception determination.  21 
F.  This section does not prevent:  22 
(1)  An insurer, health plan or utilization review organization from requiring a 23 
patient to try a generic drug, as  defined in Title 32, section 13702 -A, subsection 24 
14, prior to providing coverage for the equivalent brand name prescription drug; 25 
or 26 
(2)  A health care provider from prescribing a prescription drug that is 27 
determined to be medically necessary.  28 
7.  Rules.  The superintendent shall adopt rules to implement this section.  Rules 29 
adopted pursuant to this subsection are routine technical rules as defined in Title 5, 30 
chapter 375, subchapter 2 -A. 31 
Sec. 2.  Application.  The requirements of this Act apply to all pol icies, contracts 32 
and certificates executed, delivered, issued for delivery, continued or renewed in this 33 
State on or after January 1, 2018.  For purposes of this Act, all contracts are deemed to be 34 
renewed no later than the next yearly anniversary of the c ontract date.  35 
SUMMARY  36 
This bill requires health insurers to establish a process for prescription drug step 37 
therapy override exception determinations.  38 
 
